Author name: Shan Kohli

ABA’s Top 100 Blawg Hunt: Now Open

/ By / Uncategorized

The American Bar Association (ABA) is compiling its annual list of the Top 100 blawgs in all fields of law. The ABA is now asking for recommendations of blawgs to include in their survey; those in the survey will then be subject to a vote to select the top 100. At this stage they have opened up the chance to identify blawgs for inclusion in the nominations list. The voting comes later. The link to nominate a blawg is provided […]

ABA’s Top 100 Blawg Hunt: Now Open Read More »

A Small Step for Natco, a Giant Leap for Generic Drugs: India’s first Compulsory Licensing Application Filed

/ By / Uncategorized

In a landmark move, Natco Pharma has filed India’s first compulsory licensing application against Bayer’s patented drug Nexavar, which is used to treat liver and kidney cancer. The full ET Report which covers this is available here. Nexavar is presently available in the market for Rs. 2.85 lakhs for a one month’s course, against this Natco plans to sell its generic version, sorafenib tosylate, for just Rs. 8,900 for the same course i.e. at almost 1/32 of the cost. Approximately

A Small Step for Natco, a Giant Leap for Generic Drugs: India’s first Compulsory Licensing Application Filed Read More »

Landmark Judgment: SC issues guidelines for grant of ex parte orders

/ By / Uncategorized

The Supreme Court of India in a recent judgment, Ramrameshwari Devi & Ors. vs Nirmala Devi & Ors. has laid down guidelines for the grant of ex parte orders. We have earlier blogged about the indiscriminate nature in which courts have passed ex parte orders particularly in relation to the IPRS and PPL controversies. These can be viewed here and here and a little while earlier with respect to patent infringement cases as well. These can be here ,here and

Landmark Judgment: SC issues guidelines for grant of ex parte orders Read More »

Scroll to Top